37 results
Thumbnail

D1.189 - Does Allergen Immunotherapy Add Clinically Meaningful Benefit in Paediatric Asthma and Allergic Rhinitis? A 36-Month Real-World Comparison

Thumbnail

D1.192 - Combined Polymerized Pollen and Animal Dander Immunotherapy Improves Rhinoconjunctivitis and Asthma in Polysensitized Patients: Real-World Evidence

Thumbnail

D1.194 - Real-World Effectiveness of Polymerized Dog Allergen Immunotherapy in Allergic Rhinoconjunctivitis and Asthma

Thumbnail

D1.195 - Fc-Engagers as a targeted approach for antigen-specific immune inhibition in HDM allergy

Thumbnail

D1.197 - Safety and efficacy of a modified one-day ultra-rush protocol for the induction of Hymenoptera venom immunotherapy in patients with anaphylaxis in Switzerland

Thumbnail

D1.186 - Three years treatment with HDM injection allergen immunotherapy, omalizumab, or combination therapy in allergic asthma

Thumbnail

D1.187 - A Novel Volume-Reduced Desensitization Protocol for Pembrolizumab Hypersensitivity in Advanced Lung Cancer

Thumbnail

D1.188 - Adverse Reactions During Honey Bee Venom Immunotherapy as an Indicator of Underlying Clonal Mast Cell Disease Independent of Baseline Serum Tryptase: A Case Report

Thumbnail

D1.191 - Respiratory bacterial lysate (OM-85)-loaded dissolving microneedle array patch modulates HDM-induced allergic airway inflammation and airway hyperresponsiveness in a murine asthma model

Thumbnail

D1.198 - Efficacy of Cat Allergen Immunotherapy: A Multicenter Prospective Study

Thumbnail

D1.199 - Severe vernal keratoconjunctivitis with allergic rhinitis treated with house dust mite (HDM) sublingual immunotherapy (SLIT)

Thumbnail

D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies

Thumbnail

D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection

Thumbnail

D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper

Thumbnail

D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials

Thumbnail

D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps

Thumbnail

D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use

Thumbnail

D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study

Thumbnail

D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD

Thumbnail

D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?